The Queen has approved that Sir Gregory Winter CBE FRS be appointed Master of Trinity College, Cambridge University, in succession to Lord Rees of Ludlow who retires on 30 June 2012.
Notes for Editors
Sir Gregory Winter graduated from Trinity College in 1973, and has been a Senior Research Fellow since 1991. He is a genetic engineer and best known for his research and inventions relating to therapeutic antibodies.
His research career has been based at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, and he was until recently the Deputy Director. He has won numerous scientific awards, including the Novo Biotechnology Award, Denmark, 1986; the Emil von Behring Prize, Federal Republic of Germany, 1989; the Louis Jeantet Prize for Medicine, Switzerland, 1989; the Scheele Award of the Swedish Academy of Pharmaceutical Sciences, 1994; the King Faisal International Prize in Medicine, Saudi Arabia, 1995; the William B Coley Award, Cancer Research Institute, USA, 1999; the Baly Medal of the Royal College of Physicians, 2005; the Biochemical Society Award, 2006, and the Royal Medal of the Royal Society in 2011.
He has also founded three biotech companies: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009. He consults for several start-up biotech companies, and received the BioIndustry Association Award, UK in 2008.